We examined CD4+ cell count and plasma viral load patterns among Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2 study) participants who seroconverted, comparing participants assigned to receive tenofovir/emtricitabine with participants assigned to receive placebo. We also evaluated for antiretroviral drug resistance among the breakthrough HIV infections. Among nine seroconverters assigned to tenofovir/emtricitabine and 24 to placebo, there were no significant differences in their CD4+ cell count or viral load profiles over time. Of the four participants who seroconverted on-study while receiving tenofovir/emtricitabine, none became infected as a result of drug-resistant HIV; moreover, no resistance mutations emerged following seroconversion.
aCDC-BOTUSA, Gaborone, Botswana
bDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Correspondence to Jeffrey A. Johnson, Division of HIV/AIDS Prevention, CDC, Atlanta, Georgia, USA. Tel: +1 404 639 4976; fax: +1 404 639 1174; email: email@example.com.
Received 23 July, 2013
Revised 27 September, 2013
Accepted 27 September, 2013